Klin Farmakol Farm. 2009;23(4):187-193

Cyclosporin A: pharmacokinetics, monitoring and use of rheumatology

David Suchý1, Milan Grundmann2
1 Oddělení klinické farmakologie FN Plzeň
2 Ústav klinické farmakologie, FN Ostrava a Fakulta zdravotnických studií, Ostravská univerzita, Ostrava

Cyclosporin–A (CSA) is a cyclic polypeptide with immunosupressant properties. The main use of cyclosporine is immunosuppression for

solid organ transplantation, but also in graft versus host disease, bone marrow transplantation and variety of autoimmune disorders

eg. rheumatoid artrhrtitis, systemic lupus, psoriasis). Cyclosporin is a specific T-lymfocyte suppressor, primarily acting on T helper cells,

with a unique effect on the primary immune response. Its inhibits production of interleukin -2 (IL-2) and other cykokines by activated

lymphocytes. Cyclosporin has low water solubility, and its gastrointestinal absorption can be influenced by many variables. Microemulsion

version of cyclosporine was marketed to help reduce absorption variability.

Cyclosporin is almost completely eliminated by hepatic metabolism, mainly via the the cytochrome P450-depend mono-oxygenase

system (P450s), subfamily P450 3A4

(P450 3A4, 3A5, and newly discovered 3A43). There is no doubt that the P450s has the great effect on interindividual variability of drug

response. The most active metabolites AM1, followed by AM9, display 10–20 % of the immunosuppressive activity of cyclosporin. Monitoring

of immunosuppressant therapy in transplantology is common, cyclosporin is assayed by radioimmunoassay (RIA) or high pressure

lipid chromatography (HPLC) or newly liquid chromatography-mass spectrometry (LCMS/MS.)

Authors describes cyclosporin basic pharmacokinetic, therapeutic drug monitoring (TDM) strategies and its use in autoimmune disorders.

Keywords: cyclosporin, mechanism of action, pharmacokinetics, therapeutic drug monitoring, autoimmune disorders

Published: May 1, 2010  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Suchý D, Grundmann M. Cyclosporin A: pharmacokinetics, monitoring and use of rheumatology. Klin Farmakol Farm. 2009;23(4):187-193.
Download citation

References

  1. Dostál C, Pavelka K, Saudek F, Suchopár J, Ettler K. Cyclosporinum. remedia 2005; 15: 33-52.
  2. Schreiber SL, Crabtree GR. The mechanism of action of cyclosporin A and FK 506. Imunol Today 1992; 13: 136-142. Go to original source... Go to PubMed...
  3. Chen, Guo J, Yang M, et al. Cyclosporin A impairs dendritic cells migration by regulating chemokine receptor expression and inhibiting cyclooxygenase-2 expresion. Blood 2004; 103(2): 413-421. Go to original source... Go to PubMed...
  4. Faulds D, Goa KL, Benfield P. Cyclosporin: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in immunoregulatory disorders. Drugs 1993; 45: 953-1040. Go to original source... Go to PubMed...
  5. Yoccum DE. Cyclosporine: Clinical aplication in autoimmune diseases. Mosby-Wolfe, Philadelphia 2000.
  6. Fahr A. Cyclosporin clinical pharmacokinetics. Clin Pharmacokinett 1993; 24(6): 472-495. Go to original source... Go to PubMed...
  7. Kitahara K, Kakai S. Cyclosporine and tacrolimus for treatment of rheumatoid arthritis. Current Opinion in Rheumatology 2007; 19: 238-245. Go to original source... Go to PubMed...
  8. Maťha V, et al. Cyklosporin A, Praha Grada Publishing 1994.
  9. Dostálek M. Farmakokinetika. 1st Edition. Praha: Grada Publishing, a.s., 2006.
  10. 37. Thervet E, Legendre C, Beaune P, Anglicheau D. Cytochrome P450 3A polymorphisms and immunosuppressive drugs. Pharmacogenomics 2005; 6: 37-47. Go to PubMed...
  11. Williams JA, Cook J, Hurst SI. A significant drug-metabolizing role for CYP3A5? Drug Metab Dispos 2003; 31: 1526-1530. Go to original source... Go to PubMed...
  12. Komzáková I, Šafarčík K, Brozmanová H, Grundmann M. Terapeutické monitorování cyklosporinu A. Čes Slov Farm 2002; (51)4: 159-167.
  13. Koukalová L, Baranová J, Anzenbacher P. Lékové interakce na úrovni cytochromů P 450. Část I. Interakce na úrovni CYP 3A4. Klin Farmakol Farm 2003; 17: 151-157.
  14. Halačová M, Jedličková B, Průša R. Nová strategie terapeutického monitorování hladin cyklosporinu A v krvi u pacientů po transplantaci ledvin. Čes Slov Farm 2003; (52)6: 267-271.
  15. Down P, Kahan BD, Johnston A, et al. Optimalization of cyklosporine therapy with new Therapeutic drug monitoring strategies. Report from the international Neoral TDM Advisory Consensus Meeting (Vancouver, Nov 97).
  16. Anon. Novartis Pharmaceuticals. Neoral prescribing information. East Hanover: Novartis Pharmaceuticals 2005.
  17. Lindholm A, Kahan BD. Influence of cyklosporine pharmacokinetics, trough concentration, and AUC monitoringon outcome after kidney transplantation. Clin. Pharmacvol. Ther. 54: 205-218.
  18. Wu CY, Benet LZ, Hebert MF, et al. Differentiation of absorption and first-pass gut and hepatic metabolism in humans: studies with cyclosporine. Clin Pharmacol Ther. 1995; 58(5): 492-497. Go to original source... Go to PubMed...
  19. Kronbach T, Fischer V, Meyer UA. Cyclosporine metabolism in human liver: identification of a cytochrome P-450III gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugs. Clin Pharmacol Ther. 1988; 43(6): 630-635. Go to original source... Go to PubMed...
  20. Lindholm A. Factors influencing the pharmacokinetics of cyclosporine in man. Ther Drug Monit. 1991; 13(6): 465-477. Go to original source... Go to PubMed...
  21. Gupta SK, Manfro RC, Tomlanovich SJ, et al. Effect of food on the pharmacokinetics of cyclosporine in healthy subjects following oral and intravenous administration. J Clin Pharmacol. 1990; 30(7): 643-653. Go to original source... Go to PubMed...
  22. Jorga A, Holt DW, Yaqoob M, Whittaker C, Johnston A. A survey to determine the blood concentration of cyclosporine 2 hours postdose in stable renal transplant patients. Transplant Proc 2004; 36(10): 3239-3241. Go to original source... Go to PubMed...
  23. Komzáková I, Brozmanová H, Šafařík K, Grundnmann M. Stanovení cyklosporinu A metodou vysoce účinné kapalinové chromatografie(HPLC) Čes Slov Farm 2002; 21(4): 159-167.
  24. Halloran PF, Helms LM, Kung L, Noujaim J. The temporal profile of calcineurin inhibition by cyclosporine in vivo. Transplantation68: 1999: 1356-1361. Go to original source... Go to PubMed...
  25. Sarzi-Puttini P, D'lngianna E, Fumagalli M, et al. An open, randomized comparison study of cyclosporine A, cyciosporine A + methotrexate and cyciosporine A + hydroxychloroquine in the treatment of early severe rheumatoid arthritis. Rheumatol Int 2005; 25: 15. Go to original source... Go to PubMed...
  26. Johnston A, David OJ, Cooney GF. Pharmacokinetic validation of Neoral absorption profiling. Transplant Proc32[Suppl]: 2000: 53S-56S. Go to original source... Go to PubMed...
  27. Keown P, Niese D. Cyclosporine microemulsion increases drug exposure and red7uces acute rejection without incremental toxicity in de novo renal transplantation. International Sandimmune Neoral Study Group. Kidney Int 1998; 54: 938-944. Go to original source... Go to PubMed...
  28. Kahan BD, Dunn J, Fitts C, Van Buren D, Wombolt D, Pollak R, Carson R, Alexander JW, Choc M, Wong R, et al. Reduced inter - and intrasubject variability in cyclosporine pharmacokinetics in renal transplant recipients treated with a microemulsion formulation in conjunction with fasting, low-fat meals, or high-fat meals. Transplantation 1995; 59: 505-511. Go to original source... Go to PubMed...
  29. Levy G, Thervet E, Lake J, Uchida K. Patient management by Neoral C(2) monitoring: An international consensus statement. Transplantation 2002; 73(Suppl): S12-S18. Go to original source... Go to PubMed...
  30. Kovarik JM, Mueller EA, van Bree JB, Fluckiger SS, Lange H, Schmidt B, Boesken WH, Lison AE, Kutz K. Cyclosporine pharmacokinetics and variability from a microemulsion formulation: A multicenter investigation in kidney transplant patients. Transplantation 1994; 58: 658-663. Go to original source... Go to PubMed...
  31. Buc M. Autoimunita a autroimunitné choroby. Bratislava 2005, Veda.
  32. Panayi GS, Tugwelt P. The use of cyclosporin A microemulsion in rheumatoid arthritis: conclusions of an international review. Br J Rheumatol 1997; 36: 808-811. Go to original source... Go to PubMed...
  33. CushJJ, Tugwell P, Weinblatt M, Yocum D. US konsensus guidelines for the use of cyclosporin A in rheumatoid arthritis. J Rheumatol 1999; 26: 1176-1186. Go to PubMed...
  34. Tugwell P, Pincus T, Yocum D, et al. Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. The Methotrexate-Cyclosporine Combination Study Group. N Engl J Med 1995; 333: 137-141. Go to original source... Go to PubMed...
  35. Van den Borne BE, Landewe RB, Goei The HS, et al. Combination therapy in recent onset rheumatoid arthritis: a randomized double blind trial of the addition of low dose cyclosporine to patients treated with low dose chlor oquine. J Rheumatol 1998; 25: 1493-1498. Go to PubMed...
  36. Marchesoni A, Battafarano N, Arreghini M, et al. Radiographic progression in early rheumatoid arthritis: a 12-month randomized controlled study comparing the combination of cyclosporin and methotrexate with methotrexate alone. Rheumatology (Oxford) 2003; 42: 1545-1549. Go to original source... Go to PubMed...
  37. Gerards AH, Landewe RB, Prins AP, et al. Cyclosporin A monotherapy versus cyclosporin A and methotrexate combination therapy in patients with early rheumatoid arthritis: a double blind randomised placebo controlled trial. Ann Rheum Dis 2003; 62: 291-296. Go to original source... Go to PubMed...
  38. Miranda JM, Alvarez-Nemegyei J, Saavedra MA, et al. A randomized, double-blind, multicenter, controlled clinical trial of cyclosporine plus chloroquine vs. cyciosporine plus placebo in early-onset rheumatoid arthritis. Arch Med Res 2004; 35: 36-42. Go to original source... Go to PubMed...
  39. Karanikolas G, Charalambopoulos D, Andrianakos A, et al. Combination of cyciosporine and leflunomide versus single therapy in severe rheumatoid arthritis. J Rheumatol 2006; 33: 486-489. Go to PubMed...
  40. Hetland ML, Stengaard-Pedersen K, Junker P, et al. Combination treatment with methotrexate, cyciosporine, and intraarticular betamethasone compared with methotrexate and intraarticular betamethasone in early active rheumatoid arthritis: An investigator-initiated, multicenter, randomized, double-blind, par-allel-group, placebo-controlled study. Arthritis Rheum 2006; 54: 1401-1409. Go to original source... Go to PubMed...
  41. Forre O. and Norwegian arthritis study group. Radiologie evidence of disease modification in rheumatoid arthritis patients treated with cyclosporine: result of a 48 week multicenter study comparing low dose cyciosporine and placebo. Arthritis Rheum 1994; 37: 1506-1512. Go to original source... Go to PubMed...
  42. Pavelka K, Dostál C, Jarošová K, Štolfa J. Cyklosporin. Farmakoterapie revmatických onemocnění 2005: 117-139.
  43. Caccavo D, Lagana B, Mitterhoffer AP, et al. Long-term tratment of systemic lupus erythematosus with cyciosporin A. Arthritis and Rheum 1997; 40: 27-35. Go to original source... Go to PubMed...
  44. Fu LF, Yang LY, Chen WP, Lin CJ. Clinical efficacy of cyciosporin A Neoral in the treatment of paediatric lupus nephritis with heavy proteinuria. BrJ Rheum 1998; 37: 217-221. Go to original source... Go to PubMed...
  45. Fox DA, McCune WJ. Immunosuppressive drug therapy of systemic lupus erythematosus. Rheum Dis Clin North Am 1994; 20: 265-299. Go to original source... Go to PubMed...
  46. TsokosGC, GordonC,Smolen J. Systemic lupus erythematosus, 1th edition. Mosby, Philadelphia 2007.
  47. Salvarani C, et al. A comparison of cyclosporine, sulphasalazine, and symptomatic therapy in the treatment of psoriatic arthritis. J Rheumatol 2001; 28: 2274-2282. Go to PubMed...
  48. Fraser AD, van Kuijk AWR, Westhovens R, et al. A randomised, double blind, placebo controlled, multicentre trial of combination therapy with methotrexate plus ciclosporin in patients with active psoriatic arthritis. Ann Rheum Dis 2005; 64: 859-864. Go to original source... Go to PubMed...
  49. Štolfa J, Štork J. Psoriatická artritida a psoriáza. Praha, Maxdorf Jesenius 2007.
  50. Magulová L, Božeková L, Kriška M, et al. Lékové minterakcie v klinickej praxi. Bratislava Slovak Academic Press 2004.
  51. Vencovský J. Systémová autoimunitní onemocnění. Praha, Triton 2000.
  52. Šedová L, Štolfa J, Horák P, Pavelka K. Doporučení České revmatologické společnosti pro monitorování bezpečnosti léčby revmatoidní artritidy. Čes. Revmatol. 2009; 17: 4-15.




Clinical Pharmacology and Pharmacy

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.